by Roswell Park Comprehensive Cancer Center – MedicalXPress –
Results of a Phase I clinical trial show that patients who undergo a blood stem cell transplant involving a donor have a lower risk of relapse and lower rates of graft-versus-host disease when they receive the targeted therapy VIC-1911 along with the standard-of-care regimen that includes post-transplant cyclophosphamide and sirolimus.
Led by Shernan Holtan, MD, Chief of Blood and Marrow Transplantation, and Brian Betts, MD, Vice Chair of Strategic Initiatives for Transplant and Cellular Therapy at Roswell Park Comprehensive Cancer Center, the study appears in Blood Advances.
